Corrigendum to “Identification of potential early biomarkers of preeclampsia” [Placenta (2018) 61–71]

Timofeeva, Timofeeva A.V.; Gusar, Vladyslava A.; Kan, Kan N.Е.; Prozorovskaya, K N; Karapetyan, Anna; Bayev, Oleg R.; Chagovets, Vitaliy; Kliver, Sergei; Iakovishina, Daria Yu.; Frankevich, Vladimir; Сухих, Г. Т.

doi:10.1016/j.placenta.2018.01.007

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 17 – 35 These studies can be divided into twelve discovery studies, which used large qRT-PCR panels, microarrays, or small RNA-seq, 18 , 22 , 23 , 27 – 35 and seven targeted studies, which performed qRT-PCR on small numbers of selected miR-NAs, 17 , 19 – 21 , 24 – 26 most commonly members of the placenta-specific miRNA cluster located at chr19q13 (C19MC). 19 – 21 , 24 , 25 Eleven C19MC miRNAs were identified in four of the discovery studies (the other eight discovery studies did not identify any C19MC miRNAs), 29 , 30 , 33 , 34 but only three specific miRNAs were shared among at least two studies: hsa-miR-517c-3p and hsa-miR-518e-3p were shared between Yang et al 33 and Yang et al, 34 and hsa-miR-519a-3p was common to Yang et al 33 and Timofeeva et al 29 ( Table S1 ). Of the nineteen C19MC miR-NAs identified as differentially expressed between PE and control in at least one targeted study, five were found by two studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

Srinivasan

Treacy

Herrero

et al. 2020

Cell Reports Medicine

View full text Add to dashboard Cite

SUMMARY Development of effective prevention and treatment strategies for pre-eclampsia is limited by the lack of accurate methods for identification of at-risk pregnancies. We performed small RNA sequencing (RNA-seq) of maternal serum extracellular RNAs (exRNAs) to discover and verify microRNAs (miRNAs) differentially expressed in patients who later developed pre-eclampsia. Sera collected from 73 pre-eclampsia cases and 139 controls between 17 and 28 weeks gestational age (GA), divided into separate discovery and verification cohorts, are analyzed by small RNA-seq. Discovery and verification of univariate and bivariate miRNA biomarkers reveal that bivariate biomarkers verify at a markedly higher rate than univariate biomarkers. The majority of verified biomarkers contain miR-155–5p, which has been reported to mediate the pre-eclampsia-associated repression of endothelial nitric oxide synthase (eNOS) by tumor necrosis factor alpha (TNF-α). Deconvolution analysis reveals that several verified miRNA biomarkers come from the placenta and are likely carried by placenta-specific extracellular vesicles.

show abstract

Section: Discussionmentioning

confidence: 99%

“… 22 In the other study, the discovery cohort samples (28 cases and 26 controls) were collected after diagnosis and analyzed by small RNA-seq and the verification cohort samples (only 6 cases and 10 controls) were collected pre-symptomatically and analyzed by qRT-PCR. 29 …”

Section: Introductionmentioning

confidence: 99%

Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

Srinivasan

Treacy

Herrero

et al. 2020

Cell Reports Medicine

View full text Add to dashboard Cite

show abstract

“…Two of our top ranked miRNA univariate biomarkers, miR-423-5p and miR-20a-5p, were also over-represented in our verified set of bivariate biomarkers, which also contained a disproportionate number of miRNAs from chromosome 19. As noted above, extracellular miR-423-5p has been reported to be more highly expressed in early pregnancy in patients who later develop PE by other groups(36, 47). Our own group also identified this miRNA as the numerator of an early predictive bivariate biomarker for PE(44); we used the same convention in this prior study, where numerators were more highly expressed in PE.…”

Section: Discussionmentioning

confidence: 67%

“…For let-7b-5p, our results are consistent with Gunel et al, who also reported that let-7b-5p was present at lower levels in the plasma of PE cases compared to controls(27). However, miR-4235p has been reported in prior studies to be upregulated in maternal plasma in the first trimester of women who later developed early severe PE(36, 47) and in women diagnosed with PE(48). Guo et al also reported that miR-423-5p was expressed at higher levels in the placentas of patients with PE compared to controls and that it inhibits trophoblast migration, invasion, and proliferation via IGF2BP1(48).…”

Section: Discussionmentioning

confidence: 97%

Discovery and Verification of Extracellular microRNA Biomarkers for Diagnostic and Prognostic Assessment of Preeclampsia at Triage

Morey

Poling

Srinivasan

et al. 2023

Preprint

View full text Add to dashboard Cite

Preeclampsia (PE) is a major cause of maternal and neonatal morbidity and mortality. Current methods for evaluation of patients with suspected PE do not reliably predict which patients will later develop PE nor distinguish between PE with and without severe features. The objective of this study was to identify candidate extracellular miRNA (ex-miRNA) biomarkers for early diagnosis and prognosis of PE in a cohort of subjects presenting for evaluation of suspected PE. Small RNA-seq libraries were created from maternal serum samples, prospectively collected from participants undergoing evaluation for suspected PE between 20-40 weeks gestational age. Measurements for bivariate biomarkers, consisting of ratios of pairs of ex-miRNAs were performed. 110 bivariate ex-miRNA biomarkers passed both discovery (48 cases, 34 controls) and verification (23 cases, 18 controls) criteria. Specific biomarkers differed in their patterns of expression among different categories of hypertensive disorders in pregnancy (HDP). An iterative machine learning method was then used to identify 3 bivariate miRNA biomarkers that, when applied serially, differentiated cases from controls with a sensitivity of 93% and a positive predictive value (PPV) of 55%, and additionally distinguished between PE cases of different severity. In an independent validation cohort of 11 cases and 7 controls, these three biomarkers had a sensitivity of 91% and a PPV of 85%. We have discovered, verified, and validated 3 bivariate ex-miRNA biomarkers, which, when applied serially, enable accurate early diagnosis of preeclampsia. Bivariate ex-miRNA biomarkers can distinguish between different subtypes of HDP.

show abstract

“…( 28 ), who also reported that let-7b-5p was present at lower levels in the plasma of PE cases compared to controls. However, miR-423-5p has been reported in previous studies to be up-regulated in maternal plasma in the first trimester of women who later developed early severe PE ( 37 , 50 ) and in women diagnosed with PE ( 51 ). Guo et al.…”

Section: Discussionmentioning

confidence: 83%

Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage

Morey,

Poling,

Srinivasan

et al. 2023

Sci. Adv.

View full text Add to dashboard Cite

We report on the identification of extracellular miRNA (ex-miRNA) biomarkers for early diagnosis and prognosis of preeclampsia (PE). Small RNA sequencing of maternal serum prospectively collected from participants undergoing evaluation for suspected PE revealed distinct patterns of ex-miRNA expression among different categories of hypertensive disorders in pregnancy. Applying an iterative machine learning method identified three bivariate miRNA biomarkers ( miR-522-3p/miR-4732-5p , miR-516a-5p/miR-144-3p , and miR-27b-3p/let-7b-5p ) that, when applied serially, distinguished between PE cases of different severity and differentiated cases from controls with a sensitivity of 93%, specificity of 79%, positive predictive value (PPV) of 55%, and negative predictive value (NPV) of 89%. In a small independent validation cohort, these ex-miRNA biomarkers had a sensitivity of 91% and specificity of 57%. Combining these ex-miRNA biomarkers with the established sFlt1:PlGF protein biomarker ratio performed better than either set of biomarkers alone (sensitivity of 89.4%, specificity of 91.3%, PPV of 95.5%, and NPV of 80.8%).

show abstract

Corrigendum to “Identification of potential early biomarkers of preeclampsia” [Placenta (2018) 61–71]

Cited by 3 publications

References 0 publications

Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

Discovery and Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in Asymptomatic Women

Discovery and Verification of Extracellular microRNA Biomarkers for Diagnostic and Prognostic Assessment of Preeclampsia at Triage

Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage

Contact Info

Product

Resources

About